Edelweiss Securities puts 'buy' on Aurobindo Pharma
Revenues are expected to grow at a CAGR of 20% over FY09-11E to Rs 4,400 crore, backed by high growth in the US formulations sales and potential upside from Pfizer contract.
By ET Bureau |
Market price: Rs 828.55
Target price: Rs NA
Revenues are expected to grow at a CAGR of 20% over FY09-11E to Rs 4,400 crore, backed by high growth in the US formulations sales and potential upside from Pfizer contract.
The stock is currently trading at 11.5x FY10E and 8x FY11E adjusted EPS offering 21% upside from current levels.
Target price: Rs NA
Revenues are expected to grow at a CAGR of 20% over FY09-11E to Rs 4,400 crore, backed by high growth in the US formulations sales and potential upside from Pfizer contract.
The stock is currently trading at 11.5x FY10E and 8x FY11E adjusted EPS offering 21% upside from current levels.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
